Moody Aldrich Partners LLC Viking Therapeutics, Inc. Transaction History

Moody Aldrich Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 23, 2024	SELL	$47.39 - $80.2 $1.48 Million - $2.51 Million	-31,270 Reduced 56.1%	24,465 $1.3 Million
Q1 2024 Apr 29, 2024	BUY	$17.4 - $94.5 $969,788 - $5.27 Million	55,735 New	55,735 $4.57 Million
Q2 2023 Jul 28, 2023	SELL	$14.84 - $24.79 $138,843 - $231,935	-9,356 Reduced 4.59%	194,470 $3.15 Million
Q1 2023 Apr 27, 2023	BUY	$8.08 - $17.33 $7,328 - $15,718	907 Added 0.45%	203,826 $3.39 Million
Q4 2022 Jan 23, 2023	BUY	$2.72 - $9.4 $551,939 - $1.91 Million	202,919 New	202,919 $0

462

65.9M

6.24M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.59B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Aldrich Partners LLC with notifications on news.